Identification of a subgroup of patients at highest risk for complications after surgical cytoreduction and hyperthermic intraperitoneal chemotherapy.

Published on Aug 1, 2012in Annals of Surgery9.476
· DOI :10.1097/SLA.0b013e31825704e3
Dario Baratti38
Estimated H-index: 38
Shigeki Kusamura42
Estimated H-index: 42
+ 3 AuthorsMarcello Deraco44
Estimated H-index: 44
OBJECTIVE: To assess the influence of parietal and visceral peritonectomy procedures on moderate/severe morbidity in patients undergoing surgical cytoreducion and hyperthermic intraperitoneal chemotherapy (HIPEC) and to identify subgroups of patients at highest operative risk. BACKGROUND: Cytoreducion with HIPEC is an effective but potentially morbid treatment option for peritoneal surface malignancies. Although complication rates have recently decreased with increasing experience, risk-factors for adverse operative outcome are still poorly understood. METHODS: A prospective database of 426 combined procedures was reviewed. Multivariate analysis tested the correlation between major morbidity and 6 peritonectomies (greater and lesser omentectomy, pelvic, parietal anterior, left and right diaphragmatic peritonectomy), 14 visceral resections, 5 other operative factors, and 12 clinical variables. The extent of peritoneal involvement was quantified by peritoneal cancer index (PCI). RESULTS: Mortality and major morbidity were 2.6% and 28.2%. PCI, number of visceral resections, poor performance status, and cisplatin dose more than 240 mg independently correlated to morbidity. The type and number of parietal peritonectomies and the type of visceral resections did not correlated to complications. Major morbidity rate was 65.7% in 35 (8.2%) patients with at least 2 of the following factors: PCI greater than 30, more than 5 visceral resections, poor performance status. Morbidity was 100% in 9 patients presenting all the risk factors. CONCLUSIONS: Acceptable morbidity and low mortality may be achieved in high-volume centers. Operative outcome is mainly affected by a complex interplay of tumor, patient, and treatment-related factors. Preoperative and early intraoperative assessment of operative risk may identify a subset of patients unlikely to tolerate aggressive management.
  • References (41)
  • Citations (42)
📖 Papers frequently viewed together
470 Citations
549 Citations
10 Authors (Olivier Glehen, ..., Dominique Elias)
300 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
#2Marcello DeracoH-Index: 44
Last. Paul H. Sugarbaker (MedStar Washington Hospital Center)H-Index: 70
view all 10 authors...
BACKGROUND: Currently, no tumor-node-metastasis (TNM) staging system exists for patients with diffuse malignant peritoneal mesothelioma (DMPM). The primary objective was to formulate a clinicopathological staging system through the identification of significant prognostic parameters. METHODS: Eight international institutions with prospectively collected data on patients who underwent cytoreductive surgery and hyperthermic intraperitoneal chemotherapy contributed to the registry. Two hundred nine...
74 CitationsSource
#1Gabriel GlockzinH-Index: 18
#2Philipp RennerH-Index: 12
Last. Pompiliu PisoH-Index: 30
view all 7 authors...
Background The long-term prognosis of patients with peritoneal malignancies has greatly improved since the introduction of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Nevertheless, CRS can be associated with high postoperative morbidity. In this retrospective study, we analyzed the influence of hepatobiliary surgery as part of CRS on postoperative short-term patient outcome.
26 CitationsSource
#1Xiaojun Yang (WHU: Wuhan University)H-Index: 10
#2Chao-Qun Huang (WHU: Wuhan University)H-Index: 9
Last. Yan Li (WHU: Wuhan University)H-Index: 44
view all 10 authors...
Background This randomized phase III study was to evaluate the efficacy and safety of cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of peritoneal carcinomatosis (PC) from gastric cancer.
295 CitationsSource
#1Paul H. Sugarbaker (Washington Cancer Institute)H-Index: 70
13 CitationsSource
#1Terence C. Chua (St George's Hospital)H-Index: 36
#2Abdulaziz Al-Zahrani (St George's Hospital)H-Index: 1
Last. David L. Morris (St George's Hospital)H-Index: 67
view all 7 authors...
Background This study evaluates the accuracy of computed tomography (CT) scoring of the peritoneal cancer index (PCI) and examines its association with surgical morbidity and outcomes in pseudomyxoma peritonei.
32 CitationsSource
#1Olivier Glehen (Lyon College)H-Index: 47
#2François N. Gilly M.D. (Lyon College)H-Index: 3
Last. Dominique Elias (Institut Gustave Roussy)H-Index: 84
view all 10 authors...
BACKGROUND: Peritoneal carcinomatosis (PC) from nonovarian malignancies long has been regarded as a terminal disease. Over the past decade, new locoregional therapeutic approaches combining cytoreductive surgery with perioperative intraperitoneal chemotherapy (PIC) have evolved that have demonstrated improved survival. METHODS: A retrospective, multicenter cohort study was performed in French-speaking institutions to evaluate toxicity and principal prognostic factors after cytoreductive surgery ...
300 CitationsSource
#1Robert T. RipleyH-Index: 3
#2Jeremy L. DavisH-Index: 15
Last. Itzhak AvitalH-Index: 31
view all 6 authors...
Background The standard of care for colorectal peritoneal carcinomatosis is evolving from chemotherapy to cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with disease limited to the peritoneum. Peritoneal carcinomatosis from colorectal cancer treated with chemotherapy alone results in median survival of 5 to 13 months, whereas CRS with HIPEC for early peritoneal carcinomatosis from colorectal cancer resulted in median survival of 48-63 months and 5...
33 CitationsSource
#1Jesus Esquivel (St. Agnes Hospital)H-Index: 23
#2Terence C. Chua (UNSW: University of New South Wales)H-Index: 36
Last. Robert P. Sticca (UND: University of North Dakota)H-Index: 14
view all 20 authors...
Background Evaluation of peritoneal metastases by computed tomography (CT) scans is challenging and has been reported to be inaccurate. Methods A multi-institutional prospective observational registry study of patients with peritoneal carcinomatosis from colorectal cancer was conducted and a subset analysis was performed to examine peritoneal cancer index (PCI) based on CT and intraoperative exploration. Results Fifty-two patients (mean age 52.6 ± 12.4 years) from 16 institutions were included i...
104 CitationsSource
#1Dario Baratti (NIH: National Institutes of Health)H-Index: 38
#2Elisabetta Pennacchioli (NIH: National Institutes of Health)H-Index: 1
Last. Marcello Deraco (NIH: National Institutes of Health)H-Index: 44
view all 9 authors...
Background Unlike novel molecular-targeted therapies for metastatic gastrointestinal stromal tumors (GIST), conventional treatments for peritoneal sarcomatosis (PS) are mostly ineffective. As with carcinomatosis of epithelial origin, a rationale base supports an aggressive locoregional treatment of PS, but the use of CRS and HIPEC in this setting is still controversial. We assessed the outcome of clinically and pathologically homogeneous subsets of patients with PS uniformly treated by cytoreduc...
54 CitationsSource
#1Jan Franko (University of Pittsburgh)H-Index: 7
#2Zuhaib Ibrahim (University of Pittsburgh)H-Index: 11
Last. Herbert J. Zeh (University of Pittsburgh)H-Index: 66
view all 6 authors...
BACKGROUND: Survival benefit of cytoreductive surgery combined with hyperthermic intraperitoneal chemoperfusion was demonstrated by a prospective randomized trial for colorectal peritoneal carcinomatosis. Because of a recent substantial improvement in chemotherapy, the authors analyzed treatment options of colorectal carcinomatosis in the current era. METHODS: Consecutive patients with colorectal carcinomatosis treated by cytoreductive surgery combined with hyperthermic intraperitoneal chemoperf...
188 CitationsSource
Cited By42
#2Juan José Segura-Sampedro (UIB: University of the Balearic Islands)H-Index: 6
Last. Rafael Morales-SorianoH-Index: 2
view all 6 authors...
BACKGROUND AND OBJECTIVES: Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) is an effective but complex treatment for peritoneal metastasis (PM). Our objective was to identify risk factors for postoperative morbidity and mortality following CRS-HIPEC. METHODS: Retrospective study of prospectively collected data of patients undergoing CRS-HIPEC for PM arises from colorectal cancer between January 2008 and December 2017. Perioperative variables were correlated with ...
The extent of surgery (ES) during cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS + HIPEC) is a well-known risk factor for major postoperative morbidity. Interestingly, the reliability of surgeons to predict the ES prior to CRS + HIPEC is unknown. In this prospective, observational cohort study, five surgeons predicted the ES prior to surgery in all consecutive patients with peritoneal metastases (PM) who were scheduled for CRS + HIPEC between March 2018 and May 2019. A...
#1Toshiyuki KitaiH-Index: 20
#2Kenya YamanakaH-Index: 12
Last. Osamu InamotoH-Index: 1
view all 4 authors...
Purpose Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS + HIPEC) is the active treatment for peritoneal carcinomatosis of appendiceal origin. However, surgical management is sometimes difficult in patients with a high-tumor burden.
#1Arvind SabesanH-Index: 1
#2Seth FelderH-Index: 1
Last. Sean P. DineenH-Index: 19
view all 8 authors...
Background Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) for patients with low-grade mucinous adenocarcinoma (LGMA) is most effective when complete cytoreduction is achieved. We externally validated two radiographic scoring systems to predict resectability and assessed radiographic response to systemic chemotherapy (SCT).
1 CitationsSource
#1Philipp Horvath (University of Tübingen)H-Index: 7
#2Stefan Beckert (University of Tübingen)H-Index: 18
Last. Ingmar KönigsrainerH-Index: 21
view all 5 authors...
Resume Introduction La chirurgie de cyto-reduction incluant une resection hepatique et une chimio-hyperthermie intraperitoneale (CHIP) permet d’ameliorer la survie de certains patients, mais est grevee d’une morbidite importante et d’une mortalite non nulle. Le but de cette etude etait de rapporter les resultats de cette chirurgie simultanee et les parametres associe a la morbidite postoperatoire. Patients et methodes Il s’agit de l’analyse retrospective de 37 patients ayant eu une resection hep...
Purpose Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have become standard of care for many peritoneal malignancies in selected patients. Nevertheless, this aggressive treatment strategy is associated with significant major morbidity. The aim of the present study is to analyze the re-operation rate and clinical outcome following CRS and HIPEC.
#1Philipp Horvath (University of Tübingen)H-Index: 7
#2Stefan Beckert (University of Tübingen)H-Index: 18
Last. Ingmar KönigsrainerH-Index: 21
view all 5 authors...
Summary Aim of the study Cytoreductive surgery including liver resection and hyperthermic intraperitoneal chemotherapy provide survival benefit to selected patients but is associated with relevant morbidity and mortality rates. We aimed to report morbidity and mortality rates and parameters linked to increased morbidity. Patients and methods Retrospective analysis of 37 patients who underwent liver resection and cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy between 2006 an...
2 CitationsSource
Background. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) showed promising results in selected patients. High morbidity restrains its wide application. The aim of this study was to report postoperative infectious complications and investigate possible correlations with the preoperative nutritional status and other prognostic factors in patients with peritoneal metastases treated with CRS and HIPEC. Methods. For the study, we reviewed the clinical records of al...
#1Snita Sinukumar (Jehangir Hospital)H-Index: 4
#2Sanket Mehta (Saifee Hospital)H-Index: 6
Last. Aditi BhattH-Index: 6
view all 12 authors...
To determine factors influencing failure-to-rescue in patients with complications following cytoreductive surgery and HIPEC. A retrospective analysis of patients enrolled in the Indian HIPEC registry was performed. Complications were graded according to the CTCAE classification version 4.3. The 30- and 90-day morbidity were both recorded. Three hundred seventy-eight patients undergoing CRS with/without HIPEC for peritoneal metastases from various primary sites, between January 2013 and December ...
#1Pompiliu PisoH-Index: 30
Last. Jörg PelzH-Index: 5
view all 8 authors...
Background Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are performed for well-selected patients with peritoneal surface malignancies. This combined treatment is potentially associated with an increased rate of complications.
6 CitationsSource